One To Watch

Engage Biologics

Company Overview

A preclinical-stage genetic medicine biotech acquired by Eli Lilly in May 2026 for up to $202 million, valued for its Tethosome non-viral DNA delivery platform that achieves durable, redosable gene expression without the immunogenicity constraints of viral vectors. Engage Biologics, which operated as Engage Bio, built its entire value proposition around a single delivery innovation rather than a clinical pipeline — a deliberate platform-first strategy that paid off four years after founding. The Tethosome system addresses one of genetic medicine's most stubborn bottlenecks: getting therapeutic DNA into the nucleus efficiently enough to produce meaningful, lasting protein expression. Lilly's willingness to pay milestone-contingent consideration on top of upfront cash for a preclinical asset signals how seriously large pharma is competing for delivery differentiation.

Headquarters and Global Presence

Engage Bio was headquartered in San Carlos, California, operating as a lean preclinical research organization from its founding through its acquisition. Following the May 2026 deal close, the team and platform are being integrated into Eli Lilly's genetic medicines research engine.

Founding and History

Engage Biologics was founded in 2021 in San Carlos, California, with Will Olsen among the co-founders and serving as CEO. The company remained preclinical throughout its independent life, advancing the Tethosome platform through proof-of-concept studies in liver-targeting models including hemophilia A and hepatocellular carcinoma. The acquisition by Lilly, announced May 20, 2026, marked the company's exit — Lilly's seventh acquisition of 2026 and a clear signal of pharma's appetite for non-viral delivery assets at even the earliest stages.

Therapy Areas and Focus

Engage Bio's platform work concentrated on liver-targeted genetic medicine, with hemophilia A and hepatocellular carcinoma serving as the primary preclinical proof-of-concept indications. These disease areas share a common requirement: durable transgene expression in hepatocytes following systemic delivery. Hemophilia A, where a functional Factor VIII gene must be expressed at therapeutically relevant levels over years, is a particularly demanding test for any non-viral platform and a commercially significant one given the limitations of existing gene therapy approvals.

Technology Platforms and Modalities

The Tethosome platform is the company's defining asset. An LNP delivers two payloads simultaneously: a therapeutic DNA construct and an mRNA encoding the proprietary Tethosome protein, which acts as a nuclear trafficking chaperone, localizing the DNA cargo to the nucleus and increasing expression by more than 100-fold relative to unassisted DNA delivery. The platform's strategic advantage is immune evasion — Tethosome-delivered DNA is not detected by the cytosolic DNA sensors that typically trigger innate immune responses, enabling safe repeat dosing. Redosability is a meaningful differentiator over adeno-associated virus vectors, where pre-existing immunity and immune priming after first administration are persistent commercial and clinical constraints.

Key Pipeline and Programs

Engage Bio had no named clinical or IND-stage assets at the time of acquisition; its pipeline was entirely platform-level and preclinical. The company's primary proof-of-concept work was conducted in liver-targeting models. In hemophilia A models, Tethosome-mediated delivery of a Factor VIII transgene demonstrated sustained expression consistent with a potential functional cure for the bleeding disorder — the benchmark against which all gene therapy approaches in this indication are measured. In hepatocellular carcinoma models, the platform's ability to deliver and express DNA cargo in tumor-bearing liver tissue was explored as a potential oncology application, though this work remained at an early stage. The absence of named drug candidates should be read in context: Lilly acquired Engage for delivery infrastructure, not individual programs, and the Tethosome technology is intended to be applied across Lilly's own genetic medicine portfolio.

Recent Developments

On May 20, 2026, Eli Lilly announced the acquisition of Engage Bio in a deal valued at up to $202 million in cash, comprising an upfront payment plus development milestone-contingent consideration. The transaction was Lilly's seventh acquisition of calendar year 2026, reflecting an active M&A posture in genetic medicine delivery. Co-founder and CEO Will Olsen described the deal as the next chapter for the Engage team, whose members are being absorbed into Lilly's genetic medicines research organization alongside the Tethosome platform.

Key Personnel

Will Olsen co-founded Engage Bio and served as CEO from its 2021 founding through its acquisition by Lilly. Olsen described the Lilly deal as representing the company's next chapter and is expected to transition into Lilly's genetic medicines organization as part of the integration. Further executive detail for the broader leadership team was not disclosed publicly ahead of the acquisition close.

Strategic Partnerships

Engage Bio operated independently without disclosed external collaborations or licensing agreements prior to its acquisition. The company's sole and defining strategic transaction was its acquisition by Eli Lilly, announced May 20, 2026, for up to $202 million — a deal structured to incentivize further development milestones as the Tethosome platform is applied within Lilly's genetic medicine programs.

FAQ Section

Lilly's rationale was delivery infrastructure, not drug assets. The Tethosome platform addresses a critical bottleneck in genetic medicine — efficient, durable, redosable non-viral DNA delivery — that applies across multiple programs in Lilly's portfolio. Acquiring the capability outright, rather than licensing or building it, is consistent with Lilly's 2026 M&A pattern of buying enabling technologies early before competitive pricing drives up valuations.

Most non-viral delivery systems fail at nuclear entry: DNA delivered by LNPs into the cytoplasm is degraded or triggers innate immune sensors before it reaches the nucleus in sufficient quantity to produce therapeutic protein levels. The Tethosome solution — co-delivering an mRNA that produces a nuclear trafficking protein — is a two-payload strategy that sidesteps both problems simultaneously, achieving over 100-fold expression gains relative to unassisted DNA while remaining invisible to cytosolic DNA-sensing pathways.

AAV achieves efficient nuclear delivery but carries hard limits on payload size, triggers immune responses that preclude redosing, and has manufacturing constraints that keep costs high. Standard LNP-mRNA is redosable and scalable but produces only transient protein expression. Tethosome occupies a distinct position: it uses established LNP manufacturing, delivers DNA for durable expression, and preserves redosability by evading the immune recognition that disqualifies AAV from repeat administration.

Engage Bio demonstrated proof-of-concept in two liver-targeting disease models. In hemophilia A, Tethosome-mediated Factor VIII transgene delivery produced sustained expression at levels relevant to therapeutic benefit. In hepatocellular carcinoma models, the platform showed the ability to express DNA cargo in tumor-bearing liver tissue. Both sets of data remained preclinical and uncontrolled, but they were sufficient to validate the platform's core claims around expression potency and durability for Lilly's diligence purposes.

Engage Bio's own work focused on liver-targeted indications — hemophilia A as a primary rare disease application, and hepatocellular carcinoma as an oncology application. The liver focus is logical given that LNP-mediated delivery naturally accumulates in hepatocytes following systemic administration, the same biodistribution that made LNP-mRNA COVID vaccines effective. Under Lilly, the platform's potential scope will be determined by where Lilly chooses to apply it across its own genetic medicine pipeline.

Engage was entirely preclinical — no IND filings, no named clinical-stage assets, and no disclosed external collaborations. It was founded in 2021 and acquired in May 2026, meaning the platform progressed from concept to a $202 million acquisition in under five years entirely on preclinical data. The milestone-contingent deal structure reflects the early stage: Lilly pays more only as the technology demonstrates value inside its own programs.

The principal catalysts and risks as the Tethosome platform moves into Lilly's genetic medicine engine include:

Whether Lilly files an IND using Tethosome-delivered DNA for hemophilia A or another liver indication, which would be the first human validation of the platform
The pace and scope of integration — whether the Engage team retains scientific autonomy or is absorbed into Lilly's broader R&D structure
Whether Tethosome demonstrates competitive performance against other non-viral platforms Lilly or rivals may be developing in parallel
Achievement of the undisclosed development milestones that determine whether the full $202 million consideration is realized

Want to Update your Company's Profile?